Adoption barriers for continuous glucose monitoring and their potential reduction with a fully implanted system: Results from patient preference surveys

Clinical Diabetes

Volumn 36, Issue 1, 2018, Pages 50-58

  Engler, Robert ^a,b   Routh, Timothy L ^b   Lucisano, Joseph Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GlySens Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIDS KNOWLEDGE AND ATTITUDES SURVEY; ARTICLE; BLOOD GLUCOSE MONITORING; COST; DIABETES MELLITUS; FEMALE; FISHER EXACT TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED;

EID: 85040791332     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/cd17-0053/-/DC1     Document Type: Article

References (30)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
2. Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: overview. Diabetes Care 2014;37:9–16
3. DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–693
4. JDRF Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476
5. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34:795–800
6. JDRF Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378–1383
7. JDRF Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17–22
8. Klonoff DC, Buckingham B, Christiansen JS, et al. Continuous glucose monitoring: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:2968–2979
9. JDRF Continuous Glucose Monitoring Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009;32:1947–1953
10. Picard S, Hanaire H, Baillot-Rudoni S, et al. Evaluation of the adherence to continuous glucose monitoring in the management of type 1 diabetes patients on sensor-augmented pump therapy: the SENLOCOR study. Diabetes Technol Ther 2016;18:127–135
11. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155–3162
12. New JP, Ajjan R, Pfeiffer AF, Freckmann G. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med 2015;32:609–617
13. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005;28:1231–1239
14. Chamberlain JJ, Dopita D, Gilgen E, Neuman A. Impact of frequent and persistent use of continuous glucose monitoring (CGM) on hypoglycemia fear, frequency of emergency medical treatment, and SMBG frequency after one year. J Diabetes Sci Technol 2015;10:383–388
15. Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW; T1D Exchange Clinic Network. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 2016;39:e81–e82
16. Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther 2016;18(Suppl 2):S3–S13
17. Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 2016;59:1795–1805
18. T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care 2014;37:2702–2709
19. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinical Network. Current state of type 1 diabetes treatment in the U.S: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971–978
20. Anhalt H. Limitations of continuous glucose monitor usage. Diabetes Technol Ther 2016;18:115–117
21. T1D Exchange. Why do some people with T1D stop using a pump and CGM? [Internet] Available from https://t1dexchange.org/pages/why-do-some-people-with-t1d-stop-using-a-pump-and-cgm. Accessed 31 October 2017
22. Gonder-Frederic LA, Shepard JA, Grabman JH, Ritterband LM. Psychology, technology, and diabetes management. Am Psychol 2016;71:577–589
23. Norman DA. The Design of Everyday Things: Revised and Expanded Edition. Basic Books, New York, N.Y., Perseus Books Group, 2013
24. Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
25. Mariani HS, Layden BT, Aleppo G. Continuous glucose monitoring: a perspective on its past, present, and future applications for diabetes management. Clin Diabetes 2017;35:60–65
26. Shivers JP, Mackowiak L, Anhalt H, Zisser H. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol 2013;3:789–794
27. Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hook KK. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care 2017;40:181–187
28. JDRF Continuous Glucose Monitoring Study Group. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010;33:1269–1274
29. Roze S, Smith-Palmer J, Valentine WJ, et al. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. J Med Econ 2016;19:236–242
30. Vigersky RA. The benefits, limitation, and cost effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol 2015;9:320–330